Cancer Chemotherapy and Pharmacology

, Volume 35, Supplement 1, pp S97–S100 | Cite as

Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer

  • Claes Anderström
Session 4: State of the Art in Urinary Tract Tumors Epirubicin, Medroxyprogesterone Acetate, Prostatic Cancer

Abstract

Maximal androgen blockade (MAB) has been reported to prolong the time to progression and the duration of survival in metastatic prostatic cancer. The addition of epirubicin to MAB in such patients seems to improve the therapeutic results further. The beneficial effect of combining castration with epirubicin in metastatic cases appears questionable. In comparing the time to progession in patients treated with MAB±epirubicin versus castration ±epirubicin or estramustine, many studies reveal similar figures. Whether the results after treatment are actually improved remains controversial. In hormone-refractory cases, medroxyprogesterone acetate (MPA) alone seems superior to estramustine or prednisolone treatment. Combining MPA and epirubicin improves the results, but even if the improvement is of clinical value, it is nonetheless of limited magnitude.

Key words

Epirubicin Medroxyprogesterone acetate Prostatic cancer 

References

  1. 1.
    Anderström C, Eddeland A, Folmerz P, Hansson R, Milles S, Zackrisson B (1994) Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer — a prospective randomized study. Eur Urol (in press)Google Scholar
  2. 2.
    Benson RC, Gill GM (1986) Estramustine phosphate compared with diethylstilbestrol. Am J Clin Pathol 9: 341Google Scholar
  3. 3.
    Bouffioux CR (1982) Medroxyprogesterone acetate in prostatic cancer. Five year results in advanced untreated and oestrogenresistant cases. Exerpta Med Int Congr Ser 611:450Google Scholar
  4. 4.
    Burk K, Schultze-Seemann, W, Jonas D, Rodeck G (1989) Weekly epirubicin in patients with hormone-refractory prostatic cancer. Prog Clin Biol Res 303:277Google Scholar
  5. 5.
    Crawford ED, Nabors WL (1986) Total androgen ablation: American experiences. Urol Clin North Am 18: 55Google Scholar
  6. 6.
    Denis LJ, Carneiro de Moura JL, Bono A, Sylvester R, Whealan P, Newling D, Depauw M (1993) Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42: 119Google Scholar
  7. 7.
    Elomaa I, Kellokumpu-Lehtinen P, Rannikko S, Alftan OL (1991) Hormone-resistant metastatic prostate cancer. Eur Urol 19: 12Google Scholar
  8. 8.
    Fosså SD, Jahnsen JU, Karlsen S, Ogreid P, Haveland H, Trovåg A (1985) High dose medroxyprogesterone accate versus prednisolone in hormone-resistant prostatic cancer. Eur Urol 11: 11Google Scholar
  9. 9.
    Fosså SD, Urnes T, Kaalhus O (1987) Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate. Scand J Urol Nephrol 21: 13Google Scholar
  10. 10.
    Johansson J-E, Andersson S-O, Holmberg L (1991) High-dose medroxyprogesterone acetate versus estramustine in therapy resistant prostatic cancer: a randomized study. Br J Urol 68: 67Google Scholar
  11. 11.
    Landström M, Tomic R, Damberg J-E (1987) Effects of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R 3327 H prostatic adenocarcinoma. Eur Urol 13: 203Google Scholar
  12. 12.
    Pavone Macaluso M, Voogt HJ de, Viggiano G, Barasolo E, Lardenols B, Pauw M de, Sylvester R (1986) Comparision of diethylstilbestrol, cyproterone acetate and medroxyprogesterone in the treatment of advanced prostatic cancer. Final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136:624Google Scholar
  13. 13.
    Plummer K (1991) Epirubicin plus flutamide and orchiectomy in previously untreated advanced prostatic cancer. Semin Oncol 18 [Suppl 6]: 26Google Scholar
  14. 14.
    Robinson MRG, Chandrysekran S, Newling DWU, Richards B, Smith PH (1983) Low dose doxorubicin in the management of advanced carcinoma of the prostate. Br J Urol 55: 747Google Scholar
  15. 15.
    Tomic R, Ljungberg B, Damber J-E (1988) Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma. Scand J Urol Nephrol 22: 15Google Scholar
  16. 16.
    Torti F, Aston D, Lum BL, Kohler M, Williams R, Spaulding JT, Shortliffe L, Freiha FS (1983) Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1: 477Google Scholar
  17. 17.
    Torti FM, Shortliffe L, Carter SK (1985) A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer 56: 2580Google Scholar
  18. 18.
    Tveter KJ, Hagen S, Holme I, Klepp O, Kloster SE, Muri O, Jr, Poulsen C, Sander S, Sivertsen S, Urnes T, Ogreid P (1990) A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. Scand J Urol Nephrol 24: 243Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Claes Anderström
    • 1
  1. 1.Department of UrologyKärnsjukhusetSkövdeSweden

Personalised recommendations